Alector, Inc. (NASDAQ:ALEC) Given Consensus Rating of “Hold” by Brokerages

Alector, Inc. (NASDAQ:ALEC) has been assigned an average recommendation of “Hold” from the seven research firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $4.00.

A number of brokerages recently weighed in on ALEC. Morgan Stanley restated an “underweight” rating and set a $1.50 price objective (down from $3.00) on shares of Alector in a research note on Friday, March 7th. HC Wainwright increased their price target on Alector from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, May 9th.

Alector Price Performance

Shares of ALEC stock opened at $1.46 on Friday. Alector has a twelve month low of $0.87 and a twelve month high of $6.78. The stock has a market capitalization of $145.99 million, a price-to-earnings ratio of -1.16 and a beta of 0.71. The stock has a fifty day simple moving average of $1.24 and a two-hundred day simple moving average of $1.52. The company has a current ratio of 3.34, a quick ratio of 3.34 and a debt-to-equity ratio of 0.10.

Institutional Trading of Alector

Several hedge funds and other institutional investors have recently bought and sold shares of ALEC. Squarepoint Ops LLC acquired a new stake in Alector during the fourth quarter worth about $25,000. Tema Etfs LLC acquired a new stake in Alector during the fourth quarter worth about $27,000. Tower Research Capital LLC TRC grew its holdings in Alector by 71.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company’s stock worth $28,000 after acquiring an additional 6,096 shares during the period. CWM LLC grew its holdings in Alector by 370.7% during the first quarter. CWM LLC now owns 33,643 shares of the company’s stock worth $41,000 after acquiring an additional 26,495 shares during the period. Finally, Vontobel Holding Ltd. grew its holdings in Alector by 127.3% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $47,000 after acquiring an additional 14,000 shares during the period. 85.83% of the stock is owned by institutional investors and hedge funds.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.